Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality. Recent retrospective clinical analyses suggest that blocking the receptor activator of NF-κB (RANK) signaling pathway inhibits the growth of NSCLC and might represent a new treatment strategy.
Introduction
With over 1.5 million deaths yearly, lung cancer has become the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) representing 80-85% of cases 1 .
Although new therapies are emerging to combat lung adenocarcinoma, the main histological subtype of NSCLC, their use is currently limited to a subset of molecularly selected patients, and no specific targeted therapy has demonstrated activity against tumors carrying the most frequently mutated proto-oncogene, KRAS 2 . One interesting approach for cancer treatment is to identify actionable membrane-bound or secreted ligand-receptor systems that act in the tumor environment to promote disease progression, which can be very selectively blocked through the use of small compounds or antibodies. One such example is the tumor necrosis factor (TNF) family member, receptor activator of NF-κB (RANK) ligand (RANKL) that signals through its receptor RANK, first discovered for communication between T cells and dendritic cells 3 .
Through its receptor RANK, RANKL activates osteoclasts for bone resorption, promotes lymphocyte maturation and function, and enables mammary gland and secondary lymph node organogenesis [4] [5] [6] . A link between RANKL signaling and cancer has been established in recent years: first, and perhaps owing to its bone remodeling capabilities, the RANKL-RANK pathway facilitates bone metastasis formation 7, 8 ; second, it promotes seeding of breast tumor cells into the lungs in a T-regulatory (Treg) cell-dependent manner 9 ; third, it participates in progestindependent mammary tumor development 10, 11 . The importance of this signaling pathway in primary breast cancer is well documented, with RANKL mRNA being stabilized in response to progesterone, leading to increased RANKL protein expression that promotes tumor cell proliferation 12 and epithelial-mesenchymal transition to foster tumor cell migration 13 . In contrast, much less is known about its contribution in primary tumors from other carcinomas such as lung cancer. Recently, in a large international clinical trial of patients with advanced solid tumors (excluding breast and prostate cancer) or multiple myeloma, denosumab, a fully human monoclonal antibody that binds RANKL and blocks RANKL-RANK interaction, demonstrated activity in preventing bone-metastasis related adverse events, such as fracture or the need for radiotherapy. While this trial failed to reveal any difference in overall survival (OS) 14 , a retrospective subgroup analysis from this trial reported increased OS specifically in NSCLC patients 15, 16 . In our study, we sought to investigate the involvement of RANKL in primary tumors from NSCLC using genetically engineered mouse models.
Material and methods
Animal models K-ras LSL-G12D/WT (K) and p53 FL/FL mice in a C57BL6/J background were purchased from The Jackson Laboratory, and were bred together to obtain K-ras LSL-G12D/WT ; p53 FL/FL (KP) mice.
Lkb1 FL/FL mice in a mixed background (FVB; 129S6) were obtained from R. DePinho (The University of Texas MD Anderson Cancer Center) through the National Cancer Institute mouse repository, were backcrossed seven times to C57BL6/J and were bred with K-ras LSL-G12D/WT mice to obtain K-ras LSL-G12D/WT ; Lkb1 FL/FL (KL) mice.
Mouse treatment modalities
Mice were treated with 10 mg kg -1 RANK-Fc or Fc control, by subcutaneous injection twice weekly. Cisplatin was used at 3.5 mg kg -1 in sterile PBS by intraperitoneal injection.
Study approval
All mouse experiments were performed with the permission of the Veterinary Authority of the Canton de Vaud, Switzerland (license number VD2391).
Results and discussion

RANKL expression correlates with poor overall survival and KRAS mutation in lung adenocarcinoma
To test the hypothesis that RANKL signaling regulates the development of primary lung tumors, we interrogated two independent publicly available gene expression datasets of human lung adenocarcinoma, and one of colorectal cancer (CRC). It revealed that high expression of TNFSF11 (RANKL) was associated with a reduced OS compared to tumor samples with low expression in lung adenocarcinoma but not in CRC ( Fig. 1A and S1A). TNFRSF11A (RANK) expression was also associated with reduced OS, but only in one of the two lung datasets, whereas it was linked with better OS for CRC patients (Fig. S1B-C), suggesting a peculiar relationship between RANK/RANKL signaling and lung cancer progression that is not shared by CRC. Specific data analysis from The Cancer Genome Atlas (TCGA, https://tcgadata.nci.nih.gov/tcga/) also showed that TNFSF11 expression was significantly stronger in KRAS mutant compared to KRAS wild type tumors in lung adenocarcinoma but not in CRC ( Fig. 1B) .
KRAS mutation itself in lung adenocarcinoma is not prognostic of poor OS as reported earlier 17 ( Fig. S1D ). Recently, gene expression analysis from TCGA enabled to define biologically distinct KRAS mutant lung tumors in function of co-occurring mutations in tumor suppressors 18 .
Specifically, this analysis highlighted three different subgroups, called "KC" (mutant for KRAS and enriched for CDKN2A mutations), "KP" (mutant for KRAS and enriched for TP53 mutations) and "KL" (mutant for KRAS and enriched for LKB1 mutations). Analogies were drawn between cluster-specific biological signatures and tumors from different mouse models of oncogenic Kras-dependent lung tumorigenesis. For example, gene set enrichment analysis (GSEA) of the "KL" cluster retrieved gene signatures obtained from murine lung tumors expressing mutant Kras(G12D) and deficient for Lkb1 18 . Intrigued by these analogies, we decided to compare RANKL expression between each cluster. This analysis showed that RANKL levels were the most elevated in the "KL" cluster, stronger (but not statistically different) than the "KC" cluster, and statistically significantly (P = 9.6e-07) stronger than the "KP" cluster ( Fig. 1C ). From each of the KRAS mutant and KRAS WT group, as well as the "KC", "KL" and "KP" clusters from KRAS mutant tumors, we interrogated the TNFSF11 most positively correlated genes (Table S1 ). This analysis revealed hallmark pathways of cell cycle, mammalian target of rapamycin (mTOR) signaling, epithelial-mesenchymal transition (EMT), hypoxia and glycolysis in the KRAS mutant samples. In contrast, TNFSF11 correlated genes in KRAS WT tumor samples revealed pathways representing EMT, inflammatory and angiogenic responses and, interestingly, KRAS signaling.
KRAS mutant sub-group analysis highlighted further differences between the clusters, with enrichments for pathways of cell cycle and EMT in "KC", cell cycle and mTOR signaling in "KL", and inflammatory and immune responses, KRAS signaling and EMT in "KP" (Table S1 ).
Thus, RANKL expression is associated with poor OS in human lung adenocarcinoma, is stronger in KRAS mutant samples and the strongest when LKB1 co-occurring mutations are present.
Pharmacological blockade of RANKL inhibits tumor growth in mouse models of lung adenocarcinoma
The human data prompted us to investigate the possibility that RANKL signaling contributes to primary tumor development in lung adenocarcinoma. To test this, we decided to block RANKL-RANK interaction with a recombinant protein composed of the extracellular portion of mouse RANK fused to human Fc (RANK-Fc), first in two genetically-engineered mouse models of NSCLC, K-ras LSL-G12D/WT (designated "K" thereafter) and K-ras LSL-G12D/WT ; Lkb1 FL/FL ("KL"). In these models, tumor initiation is triggered in adult mice upon intratracheal delivery of viruses carrying the Cre recombinase, resulting in oncogenic Kras(G12D) activation (K), or Kras(G12D) activation concomitantly with deletion of tumor suppressor Lkb1 (KL). Loss of Lkb1 enables tumor progression toward aggressive adenocarcinoma, with transdifferentiation to squamous cell carcinoma in some cases [19] [20] [21] . For preclinical relevance, mice were treated with RANK-Fc or control Fc only when tumors were well established and visible by micro-computed tomography (µCT). Short term (2 weeks for K, 1 week for KL mice) RANK-Fc treatment led to a significantly diminished tumor growth rate, with tumor shrinkage (i.e. relative growth below 1) detected in multiple tumors, as monitored by µCT ( Fig. 2A ). Next, to determine if there is rapid tumor progression following initial sensitivity to RANKL inhibition, we treated the most aggressive model twice weekly with RANK-Fc or control Fc for a total duration of three weeks, and monitored tumor growth rates longitudinally by µCT. Tumor growth remained compromised, indicating a durable response of primary lung adenocarcinoma to RANKL blockade ( Fig. 2B ). This response was accompanied by a reduced proliferation of tumor cells ( Fig. 2C ). Hence, Kras mutant lung tumors expressing or not Lkb1 are sensitive to RANKL blockade.
RANKL blockade elicits long term antitumor responses in K-ras LSL-G12D/WT ; p53 FL/FL mice
To evaluate the antitumor effects of RANKL blockade in yet another model, we treated tumorbearing K-ras LSL-G12D/WT ; p53 FL/FL ("KP") mice 22 with RANK-Fc. Similarly to the effect observed in K and KL mice, KP tumors were inherently sensitive to short term RANKL blockade, although no change in tumor cell proliferation could be measured contrasting with KL tumors (Fig. 3A, B ). Phospho-Erk, a marker of advanced grade in Kras G12D , p53-deficient lung tumors 23, 24 , was reduced in tumors from KP mice treated with RANK-Fc ( Fig. 3C ). Six-week treatment follow-up indicated a long-term response to RANKL blockade in KP mice (Fig. 3D ).
Together, the results from Figures 2 and 3 demonstrate an inherent sensitivity and durable response to RANKL blockade in primary lung tumors in the mouse.
RANKL-RANK expression is elevated in tumor-associated immune cells but blockade does not evoke an antitumor immune response
Next we decided to characterize better the effect of RANKL blockade, specifically in KP that represents the most common molecular subtype of the human malignancy. Staining of tumor sections by immunofluorescence enabled us to detect each of RANK and RANKL plasma membrane protein expression heterogeneously within the tumor mass, with RANK frequently co-localizing with E-cadherin ( Fig. 4A) . To understand which cell types express Tnfsf11 (Rankl) and Tnfrsf11a (Rank) we collected lung tumors or healthy lung from KP mice, and used anti-CD45 magnetic beads to separate non-immune (CD45 -) from immune (CD45 + ) cells. This revealed a stronger expression of Tnfsf11 in CD45cells isolated from tumors, which comprise mostly but not exclusively tumor epithelial cells, compared to CD45cells from healthy lung, whereas Tnfrsf11a expression was not different (Fig. 4B ). In tumors, expression of Tnfsf11 and Tnfrsf11a was more elevated in immune than non-immune cells, with the strongest expression in B and T lymphocytes for Tnfsf11, and in myeloid cells for Tnfrsf11a (Fig. 4C, D) . Because of this strong expression in immune cells within lung tumors, we next wanted to know if treatment causes remodeling of the tumor immune microenvironment. RANK-Fc led to a significant increase in Tnfsf11 expression in non-immune cells, and a reduction in immune cells, whereas there was no perturbation in Tnfrsf11a expression ( Fig. 4E ). After two weeks of treatment, no change was observed in the proportion of B cells, whereas that of T lymphocytes diminished, which was not specific for any of the CD4 + , Treg or CD8 + subsets ( Fig. S2A-C) . RANKL blockade did not result in any significant change in the expression of Tnf, Il10 or Ifng mRNAs in CD45or CD45 + cells, and did not alter cytoplasmic expression of IFNγ or TNF proteins in CD4 + or CD8 + T cells ( Fig. S2D and E) . RANK was originally characterized in DCs and suggested to participate in DC-dependent T cell expansion, a hypothesis that was not supported by analysis of RANK deficient mice 3, 4 . Our results demonstrate that, despite elevated RANK and RANKL expression in immune cells within the tumor microenvironment, RANKL blockade only marginally remodels the immune compartment, which does not support a major role for immune cells in the antitumor response.
RANKL blockade increases the efficacy of cisplatin chemotherapy
To test the effect of combination treatment compared to monotherapy, we decided to treat tumorbearing KP mice with RANK-Fc for one week followed by one week of standard chemotherapy cisplatin with maintenance of RANK-Fc, and used µCT to compare tumor growth rates to that of tumors from mice treated with cisplatin alone. Short-term cisplatin caused a diminished tumor growth rate, as reported earlier 25 , which was not significantly different from RANK-Fc therapy ( Fig. 5A) . Combined RANK-Fc + cisplatin led to a more profound effect on tumor growth ( Fig.   5B ). When compared to cisplatin alone, combined therapy led to a significant decrease in the expression of the anti-apoptotic genes Bcl2l1 and Xiap in the tumor cell compartment, as well as Xiap in immune cells (Fig. 5C ). Hence, our results highlight the efficacy of RANKL blockade in preclinical mouse models of lung adenocarcinoma. They suggest different mechanisms of action in different tumor molecular subtypes, and that combination treatments will be more efficacious than chemotherapy alone in patients (Fig. 5D ).
We have used mouse models where tumor initiation depends on oncogenic Kras activation, because (1) KRAS is the most commonly mutated proto-oncogene in human NSCLC, (2) these models faithfully recapitulate many aspects of the development of the human disease, and (3) these models are refractory to many treatments and are thus relevant to assess new therapeutic opportunities (here RANKL blockade). Our preclinical results, combined with our bioinformatics analyses, depict a strong connection between mutant KRAS and RANKL signaling in lung adenocarcinoma, which probably does not take place in CRC. Hence our observations are generating the hypothesis that RANKL blockade will be efficient in KRAS mutant lung tumors.
An important future step will be to verify this hypothesis directly in tumor samples from patients.
Case report of a patient with stage IV NSCLC treated with denosumab monotherapy
A female patient, former smoker at 30 pack-year, presented with a middle lobe lung adenocarcinoma, EGFR wild-type, without ALK rearrangement, cT4 cN0 cM1b (lower right lobe and bone metastases in the thoracolumbar spine especially L3, pelvis, femoral collar) stage IV.
She was diagnosed on 15.03.2013 (transbronchial biopsy lower right lobe). The patient was hesitating regarding chemotherapy. While she was presenting several painful bone metastases, an initial treatment of denosumab monotherapy was introduced as the first step in her oncology management, in parallel to supportive care including lumbar spine palliative radiotherapy in March. She decided to start chemotherapy on the 21 st of May, 2 months after diagnosis. A new CT scan was performed before starting chemotherapy, 4 weeks after a unique cycle of denosumab only, showing a primary lung tumor partial response (Fig. 6A and B) . Thereafter she received systemic chemotherapy (10 cycles, 4 platinum-pemetrexed, 6 pemetrexed, with partial response and thereafter with stable disease). She died 7 months after diagnosis.
This clinical case illustrates the potential efficacy, at least in select cases, of RANKL blockade therapy even in advanced disease as monotherapy. Furthermore, the very large unplanned retrospective analysis of denosumab versus zoledronic acid in bone metastatic lung cancer 16 
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